Keyword: HPAPIs


Axplora’s Farmabios Gets cGMP Approval for New Production Unit in Italy

10.10.2023 -

Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for...

Strategy & Management

Containment Solutions for HPAPI Manufacturing

21.03.2023 -

Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs...


Lonza Completes HPAPI Expansion at Visp

29.09.2022 -

Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding...


Merck Germany Doubles HPAPI Potential

24.06.2022 -

The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical...

Chemistry & Life Sciences

Integrated Drug Development Models

13.05.2022 -

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Strategy & Management

Expansions in High-Potency API Manufacturing

14.09.2020 -

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

Chemistry & Life Sciences

Understanding the Requirements of Safe HPAPI Manufacturing

11.09.2020 -

The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable...

Chemistry & Life Sciences

The Rise of HPAPI Molecules

10.09.2020 -

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.